Resource Summary Report

Generated by RRID on Jul 29, 2026

CDK9 (C12F7)

RRID:AB_2291505
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2316, RRID:AB_2291505

Antibody Information

URL: http://antibodyregistry.org/AB_2291505

Proper Citation: Cell Signaling Technology Cat# 2316, RRID:AB_2291505

Target Antigen: CDK9

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation on 4/2018: AB_10892863.

Antibody Name: CDK9 (C12F7)

Description: This monoclonal targets CDK9

Target Organism: monkey, rat, hamster, mouse, bovine, dog, human

Clone ID: C12F7

Antibody ID: AB_2291505

Vendor: Cell Signaling Technology

Catalog Number: 2316

Record Creation Time: 20250820T010811+0000

Record Last Update: 20250820T100731+0000

Ratings and Alerts

No rating or validation information has been found for CDK9 (C12F7).

No alerts have been found for CDK9 (C12F7).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Lopez Martinez D, et al. (2025) PAF1C-mediated activation of CDK12/13 kinase activity is critical for CTD phosphorylation and transcript elongation. Molecular cell, 85(10), 1952.

Devlin JR, et al. (2025) A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation. Molecular cell, 85(17), 3256.

Zheng B, et al. (2025) BRD2 bridges TFIID and MOF-H4K16ac-containing nucleosomes to promote transcriptional initiation. Molecular cell.

Puleo N, et al. (2025) Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. Molecular cancer therapeutics, 24(4), 639.

Toure MA, et al. (2025) Targeted degradation of CDK9 potently disrupts the MYC-regulated network. Cell chemical biology, 32(4), 542.

Cannon AC, et al. (2024) Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene, 43(10), 729.

Mustafa EH, et al. (2024) Selective inhibition of CDK9 in triple negative breast cancer. Oncogene, 43(3), 202.

Raina K, et al. (2024) Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies. Cell chemical biology, 31(8), 1490.

Boddu PC, et al. (2024) Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape. Molecular cell, 84(8), 1475.

Chang Y, et al. (2024) Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. Cell reports. Medicine, 5(10), 101752.

Cannon AC, et al. (2023) Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. bioRxiv : the preprint server for biology.

Zheng B, et al. (2023) Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation. Molecular cell, 83(16), 2896.

Berry S, et al. (2022) Feedback from nuclear RNA on transcription promotes robust RNA concentration homeostasis in human cells. Cell systems, 13(6), 454.

Yang Y, et al. (2022) Structural basis of RNA conformational switching in the transcriptional regulator 7SK RNP. Molecular cell, 82(9), 1724.

Lu WC, et al. (2022) AKT1 mediates multiple phosphorylation events that functionally promote HSF1 activation. The FEBS journal, 289(13), 3876.

Richters A, et al. (2021) Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell chemical biology, 28(2), 134.

Veo B, et al. (2021) Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. Cell reports, 35(4), 109013.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell reports, 34(1), 108532.

Zhu C, et al. (2021) Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1. Cell reports, 34(7), 108749.

Wang X, et al. (2021) DDB1 binds histone reader BRWD3 to activate the transcriptional cascade in adipogenesis and promote onset of obesity. Cell reports, 35(12), 109281.